50mg Pegylate Recombinant Human ErythropoietinSolution Injection

Name: 50mg Pegylate Recombinant Human ErythropoietinSolution Injection
Brand: BIOZEST HEALTHCARE PVT LTD
Price: 2300 INR
Availability: InStock

Price 2300 INR/ Unit

Get a Price/Quote

MOQ : 5 Units

50mg Pegylate Recombinant Human ErythropoietinSolution Injection Trade Information

Minimum Order Quantity
5 Units

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Units Per Month

Delivery Time
7 Days

Main Domestic Market
All India

50mg Pegylate Recombinant Human ErythropoietinSolution Injection About

Utilise this extraordinary offer on our 50mg Pegylate Recombinant Human Erythropoietin Solution Injection, expertly crafted in India! Featured for its enviable efficacy, this liquid formulation comes at a reduced price without compromising quality. Each 0.3 ml injection delivers an ace 50g dosage, specifically recommended for anemia related to CKD. Follow dosage guidelines as advised for optimal results. Store in a dry place to maintain effectiveness. From a trusted distributor and supplier in India, this solution exemplifies both innovation and affordability for superior patient care.

Advanced Surface Application and Key Features

This Recombinant Human Erythropoietin Solution Injection is intended for parenteral (injectable) use, ensuring direct absorption and effectiveness. It is designed for simple administration under professional guidance. Noteworthy special features include advanced pegylation technology, which allows for sustained efficacy and reduced dosing frequency. The products ace formulation makes it an enviable addition to any clinical setting, catering specifically to anemia patients with chronic kidney disease (CKD), while its liquid nature ensures rapid onset of action.

Sample Availability and International Shipping Highlights

Samples of the 50mg Pegylate Recombinant Human Erythropoietin Solution Injection are available for evaluation, offering transparency and reassurance for bulk buyers. Its main export markets include Asia, Africa, and the Middle East, ensuring broad access. Shipments depart from major Indian FOB ports, supported by swift express shipping and reliable goods transport solutions. The products competitive valuation underscores its value in global markets, combining efficient delivery with consistent quality for healthcare professionals and distributors worldwide.

FAQs of 50mg Pegylate Recombinant Human ErythropoietinSolution Injection:

Q: How should the 50mg Pegylate Recombinant Human Erythropoietin Injection be administered?

A: This injection is intended for parenteral (injectable) use and should be administered under the supervision or guidance of a qualified healthcare professional, following specific dosage guidelines.

Q: What are the primary benefits of using this featured recombinant human erythropoietin solution?

A: The primary benefits include effective management of anemia, especially in patients with chronic kidney disease (CKD), reduced dosing frequency due to pegylation, and an enviable safety and efficacy profile.

Q: Where should this injection be stored to maintain its potency?

A: This product should be stored in a dry place as per the provided storage instructions to ensure its stability and effectiveness until use.

Q: When is this solution most recommended for patients?

A: This injection is recommended by healthcare providers primarily for patients suffering from anemia, particularly those with chronic kidney disease, as determined through medical evaluation.

Q: What is the process for ordering and shipping this injection internationally?

A: Interested buyers can request samples for evaluation. Bulk orders are shipped from Indian FOB ports and supported by express shipping and efficient goods transport, ensuring timely and secure global delivery.

Q: How can distributors and suppliers benefit from featuring this product?

A: Distributors and suppliers benefit from its reduced price, consistent quality, international appeal, and demand for advanced anemia solutions, making it a highly marketable addition to their pharmaceutical portfolio.

Tell us about your requirement